PDCD1 and ovarian carcinoma: Nivolumab, an anti-PD-1 antibody, demonstrated an efficacy in a proportion of relapsed platinum-resistant ovarian cancer patients, with a median progression-free survival time of 3.5 months (95% CI, 1.7 to 3.9 months), and a median overall survival time of 20.0 months[39].